Gold75
2021-12-21
Good
BeiGene to receive up to $1 billion in oncology deal with Novartis
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":693676624,"tweetId":"693676624","gmtCreate":1640019492673,"gmtModify":1640019493086,"author":{"id":3576993112269247,"idStr":"3576993112269247","authorId":3576993112269247,"authorIdStr":"3576993112269247","name":"Gold75","avatar":"https://static.tigerbbs.com/3e12eb0f20c1c6eecc3de5d5be4a1184","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":39,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good </p></body></html>","htmlText":"<html><head></head><body><p>Good </p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693676624","repostId":2192118114,"repostType":4,"repost":{"id":"2192118114","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640001240,"share":"https://www.laohu8.com/m/news/2192118114?lang=&edition=full","pubTime":"2021-12-20 19:54","market":"us","language":"en","title":"BeiGene to receive up to $1 billion in oncology deal with Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2192118114","media":"Dow Jones","summary":"BeiGene Ltd. $(BGNE)$ said Monday it had entered an agreement with Swiss drug company Novartis Pharm","content":"<p>BeiGene Ltd. <a href=\"https://laohu8.com/S/BGNE\">$(BGNE)$</a> said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG (NOVN.EB) to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China. \"Ociperlimab is an investigational potent TIGIT inhibitor with intact Fc function, believed to be critical for the anti-tumor activities of TIGIT antibodies,\" the companies said in a joint statement. Beijing-based BeiGene will receive an upfront payment of $300 million up to $700 million more on exercise by Novartis of a time-based option prior to mid-2023. After that it will be eligible for up to $745 million for reaching certain regulatory milestones, and $1.15 billion for sales milestones and royalties.</p>\n<p>U.S.-listed shares of BeiGene were up 2.3% premarket.</p>\n<p><img src=\"https://static.tigerbbs.com/f9214b86b6b7c704b07a2e7637c99851\" tg-width=\"707\" tg-height=\"603\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene to receive up to $1 billion in oncology deal with Novartis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene to receive up to $1 billion in oncology deal with Novartis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 19:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeiGene Ltd. <a href=\"https://laohu8.com/S/BGNE\">$(BGNE)$</a> said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG (NOVN.EB) to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China. \"Ociperlimab is an investigational potent TIGIT inhibitor with intact Fc function, believed to be critical for the anti-tumor activities of TIGIT antibodies,\" the companies said in a joint statement. Beijing-based BeiGene will receive an upfront payment of $300 million up to $700 million more on exercise by Novartis of a time-based option prior to mid-2023. After that it will be eligible for up to $745 million for reaching certain regulatory milestones, and $1.15 billion for sales milestones and royalties.</p>\n<p>U.S.-listed shares of BeiGene were up 2.3% premarket.</p>\n<p><img src=\"https://static.tigerbbs.com/f9214b86b6b7c704b07a2e7637c99851\" tg-width=\"707\" tg-height=\"603\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1500":"做空集合股","BK4505":"高瓴资本持仓","BK1161":"生物科技","BK4139":"生物科技","06160":"百济神州","BK4526":"热门中概股","BGNE":"百济神州","BK4504":"桥水持仓","BK4007":"制药","BK1583":"高瓴概念","BK4532":"文艺复兴科技持仓","BK1588":"回港中概股","NVS":"诺华","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192118114","content_text":"BeiGene Ltd. $(BGNE)$ said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG (NOVN.EB) to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis oncology treatments in China. \"Ociperlimab is an investigational potent TIGIT inhibitor with intact Fc function, believed to be critical for the anti-tumor activities of TIGIT antibodies,\" the companies said in a joint statement. Beijing-based BeiGene will receive an upfront payment of $300 million up to $700 million more on exercise by Novartis of a time-based option prior to mid-2023. After that it will be eligible for up to $745 million for reaching certain regulatory milestones, and $1.15 billion for sales milestones and royalties.\nU.S.-listed shares of BeiGene were up 2.3% premarket.","news_type":1},"isVote":1,"tweetType":1,"viewCount":691,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/693676624"}
精彩评论